Ask AI
ProCE Banner Activity

Think You Know JAK? Essential Evidence to Aid Your Clinical Implementation of JAK Inhibitors in Atopic Dermatitis, Alopecia Areata, and Vitiligo

Slideset

These expert-curated slides explore the efficacious and safe use of JAK inhibitors in several dermatologic conditions, including atopic dermatitis, alopecia areata, and vitiligo. Understand the latest data and learn how to safely integrate these therapies in your practice by optimizing patient selection, risk assessment, shared decision-making, and monitoring to support patients’ individualized care and long-term disease control.

Released: July 29, 2026

Continue Activity

Share

Provided by

Provided by Partners for Advancing Clinical Education (Partners), in partnership with Decera Clinical Education and Smart Patients.

ProCE Banner

Supporters

Supported by an independent educational grant from AbbVie.

AbbVie

Partners

Decera Clinical Education

ProCE Banner

Smart Patients

ProCE Banner

Target Audience

This activity is intended for nurse practitioners and physician associates who are involved in the management of patients with alopecia areata, atopic dermatitis, and vitiligo.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Incorporate long-term safety and efficacy data for JAK inhibitors into treatment strategies for patients with atopic dermatitis

  • Evaluate recent clinical evidence for current and emerging JAK inhibitors in alopecia areata

  • Identify patients with vitiligo most likely to benefit from JAK inhibitor therapies based on emerging clinical trial evidence

  • Determine the role of JAK-STAT signaling in the pathophysiology of AA, AD, and vitiligo

  • Develop appropriate monitoring plans for patients with AA, AD, and vitiligo receiving JAK inhibitor therapy

  • Educate patients about the potential risks and benefits of JAK inhibitor therapies in AA, AD, and vitiligo